Sanofi: presents data for pompe disease
(CercleFinance.com) - Sanofi announces new data at the 28th Annual Congress of the World Muscle Society 2023 (WMS) in Charleston, South Carolina, US.
The data demonstrates the long-term efficacy of Nexviazyme (avalglucosidase alfa) in the treatment of Pompe disease.
In the US, Nexviazyme is currently being evaluated in Phase 3 clinical trials for infantile Pompe disease.
Key data shared at WMS come from the Phase 3 COMET trial evaluating the efficacy, safety and long-term durability of Nexviazyme in people living with late-onset Pompe disease.
Data collected over nearly three years show that patients who started treatment with Nexviazyme (whether new to the treatment or already treated), experienced an improvement or stabilization of their respiratory function and mobility.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The data demonstrates the long-term efficacy of Nexviazyme (avalglucosidase alfa) in the treatment of Pompe disease.
In the US, Nexviazyme is currently being evaluated in Phase 3 clinical trials for infantile Pompe disease.
Key data shared at WMS come from the Phase 3 COMET trial evaluating the efficacy, safety and long-term durability of Nexviazyme in people living with late-onset Pompe disease.
Data collected over nearly three years show that patients who started treatment with Nexviazyme (whether new to the treatment or already treated), experienced an improvement or stabilization of their respiratory function and mobility.
Copyright (c) 2023 CercleFinance.com. All rights reserved.